Biohaven Pharmaceutical Holding Co Ltd to Post Q1 2020 Earnings of ($2.04) Per Share, Oppenheimer Forecasts (NYSE:BHVN)

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Investment analysts at Oppenheimer increased their Q1 2020 earnings estimates for Biohaven Pharmaceutical in a research note issued to investors on Monday, February 10th. Oppenheimer analyst E. Rajavelu now expects that the company will post earnings of ($2.04) per share for the quarter, up from their prior forecast of ($2.12). Oppenheimer has a “Market Perform” rating and a $51.00 price objective on the stock. Oppenheimer also issued estimates for Biohaven Pharmaceutical’s Q2 2020 earnings at ($2.04) EPS, Q3 2020 earnings at ($2.06) EPS, Q4 2020 earnings at ($2.02) EPS, FY2020 earnings at ($8.16) EPS and FY2021 earnings at ($6.80) EPS.

BHVN has been the topic of a number of other research reports. William Blair reissued a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, December 10th. Goldman Sachs Group cut their target price on shares of Biohaven Pharmaceutical from $89.00 to $76.00 and set a “buy” rating on the stock in a research note on Monday, February 10th. Piper Jaffray Companies reissued a “buy” rating and issued a $100.00 target price on shares of Biohaven Pharmaceutical in a research note on Monday, December 23rd. Leerink Swann raised their target price on shares of Biohaven Pharmaceutical from $62.00 to $64.00 and gave the company an “outperform” rating in a research note on Friday, December 6th. Finally, Wedbush reissued a “buy” rating and issued a $75.00 target price on shares of Biohaven Pharmaceutical in a research note on Wednesday, January 29th. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Biohaven Pharmaceutical currently has an average rating of “Buy” and an average target price of $69.23.

Shares of BHVN opened at $45.33 on Thursday. The firm has a market cap of $2.39 billion, a PE ratio of -4.79 and a beta of 0.47. The company’s fifty day moving average is $52.89 and its two-hundred day moving average is $47.82. Biohaven Pharmaceutical has a fifty-two week low of $36.69 and a fifty-two week high of $67.86.

A number of institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its position in shares of Biohaven Pharmaceutical by 11.7% in the 3rd quarter. Rhumbline Advisers now owns 48,039 shares of the company’s stock worth $2,004,000 after purchasing an additional 5,022 shares during the last quarter. Columbus Circle Investors increased its position in shares of Biohaven Pharmaceutical by 15.9% in the 4th quarter. Columbus Circle Investors now owns 23,593 shares of the company’s stock worth $1,284,000 after purchasing an additional 3,235 shares during the last quarter. GW&K Investment Management LLC increased its position in shares of Biohaven Pharmaceutical by 41.5% in the 3rd quarter. GW&K Investment Management LLC now owns 146,376 shares of the company’s stock worth $6,107,000 after purchasing an additional 42,896 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Biohaven Pharmaceutical by 18.9% in the 3rd quarter. California State Teachers Retirement System now owns 60,947 shares of the company’s stock worth $2,543,000 after purchasing an additional 9,687 shares during the last quarter. Finally, Voya Investment Management LLC increased its position in shares of Biohaven Pharmaceutical by 61.2% in the 3rd quarter. Voya Investment Management LLC now owns 413,580 shares of the company’s stock worth $17,254,000 after purchasing an additional 157,079 shares during the last quarter. 92.79% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Robert Berman sold 125,000 shares of Biohaven Pharmaceutical stock in a transaction on Monday, December 30th. The shares were sold at an average price of $53.22, for a total transaction of $6,652,500.00. Following the sale, the insider now owns 125,341 shares of the company’s stock, valued at approximately $6,670,648.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Eric Aguiar sold 6,729 shares of Biohaven Pharmaceutical stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $52.20, for a total transaction of $351,253.80. The disclosure for this sale can be found here. Insiders have sold a total of 176,544 shares of company stock worth $9,506,726 in the last ninety days. 23.90% of the stock is currently owned by insiders.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Story: Gross Domestic Product (GDP)

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.